GSK Voluntary Recall of Menjugate® Liquid vaccine Lot #150401

We have received reports of anaphylaxis observed over a short time-period in three teenage patients receiving Menjugate® Liquid (meningococcal serogroup C) vaccine. We understand that all three patients have been successfully treated by healthcare professionals.

Patient safety is GSK’s first priority and we have therefore initiated a voluntary product recall for the affected batch of Menjugate® Liquid vaccine (lot 150401) which was distributed only in Canada from 6 January to 29 February 2016. GSK is working closely with Health Canada to ensure the quick and effective recall of the vaccine stock. We are also updating the health authorities in all other countries where Menjugate® Liquid is available.

At the same time, GSK is conducting an in-depth investigation relating to this batch of vaccine. Other vaccines, including other Menjugate® Liquid vaccine lots, manufactured and distributed by GSK appear unaffected by this issue. We continue to monitor the situation closely.

Anaphylaxis following vaccination is a very rare event, with around 1 to 10 cases per million vaccine doses administered. People who may have concerns about receiving Menjugate® Liquid vaccine should contact their healthcare professional for advice.

We are working with relevant authorities to ensure that vaccines continue to be available to help protect patients from meningococcal serogroup C.

GSK enquiries 

Corporate Communications +1 905-819-3363 (Mississauga)  
  +1 450-680-4812 (Laval)